独バイオ企業Evotec（ハンブルク）は9日、新薬候補の探索で米名門イェール大学と戦略提携したと発表した。有望な候補物質の開発に成功した場合は製薬会社と提携して臨床試験と商品化を委託。開発の進捗に応じたマイルストーンなどを受け取る。
\
イェール大学とは中枢神経疾患、代謝疾患、免疫疾患、がんの分野で新薬候補を探索する。Evotecはすでに米ハーバード大学と提携して糖尿病性腎症の候補物質を開発。臨床試験などを昨年、米製薬大手Johnson & Johnsonに委ねた。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |